Unintended Real Effects of EDGAR: Evidence from Corporate Innovation

被引:2
|
作者
Dambra, Michael [1 ]
Mihov, Atanas [2 ]
Sanz, Leandro [3 ]
机构
[1] Univ Buffalo, SUNY, Sch Management, Dept Accounting & Law, Buffalo, NY 14260 USA
[2] Univ Kansas, Sch Business, Finance Acad Area, Lawrence, KS USA
[3] Univ Notre Dame, Mendoza Coll Business, Dept Finance, Notre Dame, IN USA
来源
ACCOUNTING REVIEW | 2024年 / 99卷 / 06期
关键词
corporate innovation; research and development; patents; EDGAR financial reporting; disclosure processing costs; proprietary costs; dissemination costs; RESEARCH-AND-DEVELOPMENT; PRIVATE FIRMS; DISCLOSURE; MARKET; INFORMATION; COSTS; PERFORMANCE; SPILLOVERS; GROWTH; MODEL;
D O I
10.2308/TAR-2023-0310
中图分类号
F8 [财政、金融];
学科分类号
0202 ;
摘要
We study the real effects on innovation of a transformative change in corporate disclosure dissemination, the implementation of the SEC's EDGAR system. On the one hand, increased disclosure dissemination can lower firms' cost of capital, thereby stimulating innovative activity. On the other hand, increased dissemination can exacerbate proprietary disclosure costs, reducing firms' incentives to innovate. We show that treated firms reduce innovation investment following EDGAR's implementation. In contrast, EDGAR reporting firms' innovation investment cuts are met with an increase in innovation investment by their technology rivals. Consistent with an increase in proprietary costs, EDGAR-filers disclose less about their innovation activities. We also find evidence of a redistribution of innovative activity from public to private firms not subject to EDGAR disclosure requirements. Overall, our results are consistent with increased disclosure dissemination crowding out investment in innovative projects, whose returns negatively depend on information spillovers.
引用
收藏
页码:75 / 99
页数:25
相关论文
共 50 条
  • [31] Mercantile culture and corporate innovation: evidence from China
    Wang, Jinghua
    Mao, Ning
    APPLIED ECONOMICS LETTERS, 2019, 26 (17) : 1393 - 1401
  • [32] IPO underpricing and corporate innovation: evidence from China
    Wu, Di
    Zhao, Qifeng
    ECONOMICS OF INNOVATION AND NEW TECHNOLOGY, 2024, 33 (06) : 866 - 888
  • [33] Population aging and corporate innovation: evidence from China
    Zhang, Bo
    Zhou, Ruixue
    Yang, Limei
    Zhang, Ximeng
    ASIA-PACIFIC JOURNAL OF ACCOUNTING & ECONOMICS, 2023, 30 (04) : 986 - 1007
  • [34] The role of human capital: Evidence from corporate innovation
    Liu, Tong
    Mao, Yifei
    Tian, Xuan
    JOURNAL OF EMPIRICAL FINANCE, 2023, 74
  • [35] Organization Capital and Corporate Innovation: Evidence from China
    Cui, Huijie
    Dai, Lixuan
    Zhang, Yanan
    FINANCE RESEARCH LETTERS, 2021, 43
  • [36] Corporate misconduct and innovation: Evidence from the pharmaceutical industry
    Unsal, Omer
    Hippler, William J.
    RESEARCH IN INTERNATIONAL BUSINESS AND FINANCE, 2024, 71
  • [37] Monopoly and corporate innovation: evidence from antitrust law
    Yu, Minggui
    Huang, Yujing
    Zhong, Huijie
    Zhang, Qing
    NANKAI BUSINESS REVIEW INTERNATIONAL, 2022, 13 (01) : 58 - 78
  • [38] Impact of Seniority on Corporate Innovation: Evidence from China
    Ying, Qianwei
    He, Lili
    Li, Yaoqin
    Yousaf, Tahir
    PROCEEDINGS OF THE SIXTEENTH INTERNATIONAL CONFERENCE ON MANAGEMENT SCIENCE AND ENGINEERING MANAGEMENT, VOL 2, 2022, 145 : 172 - 187
  • [39] Internal control and corporate innovation: evidence from China*
    Li, Ping
    Shu, Wei
    Tang, Qingquan
    Zheng, Ying
    ASIA-PACIFIC JOURNAL OF ACCOUNTING & ECONOMICS, 2019, 26 (05) : 622 - 642
  • [40] Financial misconduct and corporate innovation: evidence from China
    Mbanyele, William
    Wang, Fengrong
    CHINESE MANAGEMENT STUDIES, 2024, 18 (04) : 1021 - 1046